Dengue Fever

• Initial viral replication and innate immune activation: Following mosquito inoculation, dengue virus replicates primarily in dendritic cells and macrophages within lymph nodes draining the bite site. The virus utilizes receptor-mediated endocytosis via DC-SIGN and other pattern recognition receptors to enter target cells. Viral replication triggers robust innate immune responses through TLR3 and RIG-I-like receptor pathways, leading to type I interferon (IFN-α/β) and pro-inflammatory cytokine (TNF-α, IL-6, IL-8) production. This innate response typically contains primary infection within 3-7 days; however, incomplete viral clearance and continued cytokine production drive the systemic manifestations observed during the febrile phase.

• Vascular permeability crisis and plasma leakage: The transition from febrile phase to critical phase (days 3-7 of illness) is characterized by a dramatic, transient increase in vascular permeability mediated by multiple mechanisms. Endothelial dysfunction occurs through direct viral infection of endothelial cells and potent vasoactive mediator release including histamine, bradykinin, and leukotrienes. Cross-reactive antibody-dependent enhancement (ADE) is a critical mechanism in secondary dengue infection: pre-existing non-neutralizing antibodies from prior dengue exposure bind to dengue virions, enhancing Fc-receptor-mediated uptake into B cells and macrophages, dramatically increasing viral replication and cytokine output (100-1000 fold amplification). Complement activation through both classical and alternative pathways generates C3a and C5a anaphylatoxins, further increasing permeability. Soluble mediators including angiopoietin-2, VEGF, and VE-cadherin disruption compromise tight junctions between endothelial cells, allowing plasma extravasation into interstitial spaces. This plasma leakage is typically transient (24-48 hours) and self-limited as antibodies mount and viremia clears; however, severe hypovolemia during this window precipitates shock in a subset of patients.

• Thrombocytopenia and hemostatic dysfunction: Dengue directly suppresses bone marrow megakaryopoiesis through viral infection and TNF-α-mediated apoptosis of megakaryocyte precursors, resulting in thrombocytopenia that typically nadir around days 3-5 of illness (platelet counts often 20,000-100,000/μL in severe dengue). Platelet dysfunction occurs through enhanced apoptosis via Fas-FasL interactions and reduced platelet activation in response to collagen and thrombin. Additionally, dengue infection directly damages endothelial cells lining small vessels, exposing subendothelial collagen and triggering platelet activation and consumption. Concurrent coagulopathy develops through consumption of clotting factors during activation of the extrinsic pathway (evidenced by prolonged PT), decreased synthesis of vitamin K-dependent factors (PT > aPTT), and elevated fibrin degradation products indicating fibrinolysis. The combination of thrombocytopenia, platelet dysfunction, endothelial damage, and coagulopathy creates a profound bleeding diathesis characterized by spontaneous petechiae, mucosal bleeding, and in severe cases, gastrointestinal hemorrhage.

• Immune-mediated tissue damage and organ dysfunction: While viral cytopathic effects contribute to cellular injury, dengue-associated organ dysfunction (hepatic, renal, myocardial) results primarily from immune-mediated damage rather than direct viral destruction. Hepatic dysfunction manifests as markedly elevated transaminases (ALT/AST often 1000-3000 IU/L), elevated bilirubin, and coagulopathy reflecting both direct hepatocyte infection and inflammatory infiltration with CD8+ T cells and macrophages. Hepatic necrosis correlates with severity of dengue hemorrhagic fever rather than viral load. Acute kidney injury (occurring in 1-5% of dengue hemorrhagic fever cases) develops through hypovolemic prerenal azotemia during shock, direct viral replication in renal tubules with tubular necrosis, and immune-complex deposition in glomeruli. Myocardial involvement ranges from subclinical myocarditis (evidenced by troponin elevation in 15-25% of severe dengue) to overt cardiogenic shock and dysrhythmias, driven by inflammatory infiltration and cytokine-mediated myocyte dysfunction rather than viral replication. The critical phase typically resolves as viremia clears and adaptive immune responses mount; patients who survive the critical phase characteristically show rapid clinical improvement within 24-72 hours.

• Dengue virus serotypes (DENV-1, DENV-2, DENV-3, DENV-4): All four serotypes cause identical clinical presentations, though DENV-2 and DENV-3 are epidemiologically associated with higher rates of dengue hemorrhagic fever and dengue shock syndrome in some populations. Infection with one serotype confers lifelong homologous immunity but provides only brief (3-6 month) heterologous protection against other serotypes. The sequential infection pattern drives the epidemiologic observation that secondary dengue infection carries substantially higher risk of hemorrhagic manifestations compared to primary infection.

• Prior dengue infection and secondary dengue: The most significant risk factor for severe dengue is secondary (or higher-order) dengue infection occurring in a person with prior infection by a different dengue serotype. Secondary infection increases risk of dengue hemorrhagic fever and dengue shock syndrome 15-80 fold compared to primary infection through the mechanism of antibody-dependent enhancement. The temporal relationship between primary and secondary infection affects severity risk; infection occurring 1-4 years after primary infection carries highest hemorrhagic risk, while infection >10 years after primary infection demonstrates lower risk. This relationship explains the age pattern of severe dengue epidemiology: in endemic areas with high transmission, severe dengue paradoxically predominates in children aged 2-14 years (age of secondary infection), while in areas with lower transmission intensity, adults represent the majority of hemorrhagic cases.

• Age and host genetics: Infants aged 6-12 months born to dengue-immune mothers possess maternally-derived antibodies that increase ADE risk during primary infection, explaining increased severity in this cohort. Host genetic factors including HLA polymorphisms, TNF-α gene variants, and mutations in genes regulating interferon responses influence individual susceptibility to severe dengue, though specific genetic markers for clinical use remain undefined.

• Demographic and geographic factors: Dengue is endemic in tropical regions between approximately 35°N and 35°S latitude, with expansion of endemic zones northward in recent decades due to climate change. Aedes aegypti breeding in urbanized environments with inadequate water sanitation creates explosive epidemic potential; vector competence increases significantly at ambient temperatures of 26-30°C (optimal for viral replication within the mosquito). Male-to-female transmission ratio is approximately 1:1; however, pregnant women infected with dengue have increased risk of adverse fetal outcomes including prematurity, intrauterine growth restriction, and congenital dengue infection.

• Travel history and timing: Non-immune travelers to endemic regions represent a cohort at high risk for primary dengue infection; however, their risk of dengue hemorrhagic fever remains low (estimated <1% of primary infections). Dengue incubation period of 3-14 days (median 4-6 days) means that symptomatic travelers typically develop symptoms after returning home, making dengue a critical diagnosis to consider in febrile returned travelers from endemic regions.

• Febrile phase (days 1-3 of illness, "saddle-back" fever pattern): Abrupt onset of high fever (often 39-40°C) accompanied by severe myalgias and arthralgias (arthralgia so prominent that dengue is historically called "breakbone fever"), intense frontal or retro-orbital headache, and photophobia. The fever pattern typically shows daily temperature swings of 1-2°C with morning remissions. Myalgias predominantly affect large joints (shoulders, knees, hips) and lower back, distinguishing dengue from other arboviral infections. Gastrointestinal symptoms including anorexia, nausea, vomiting, and mild diarrhea appear in 30-50% of cases. Rash may appear during the febrile phase or during defervescence; the characteristic "island of white in a sea of red" maculopapular rash typically spares palms and soles, though this distinction is not absolute. Mild conjunctival erythema (without exudate) occurs in approximately 25% of cases.

• Critical phase (days 3-7 of illness, "plasma leakage phase"): This phase begins with defervescence, which paradoxically marks clinical deterioration in severe dengue—a critical teaching point for boards. As fever subsides, plasma leakage peaks, manifesting as:
• Hemorrhagic manifestations: Petechiae (typically appearing first on lower extremities, axillae, and oral mucosa), easy bruising with minor trauma, mucosal bleeding (epistaxis, gingival bleeding, hemoptysis), and hematemesis/melena in severe cases
• Circulatory compromise: Expanding hematocrit by >20% compared to baseline reflects hemoconcentration from plasma loss; progressive hematocrit elevation indicates ongoing leakage and hypovolemia. Patients develop tachycardia, weak pulse pressure, and orthostatic hypotension before overt hypotension develops. Dengue shock syndrome is defined as signs of circulatory insufficiency (systolic blood pressure <90 mmHg in adults, age-adjusted in children) with evidence of plasma leakage (elevated hematocrit, pleural effusion, ascites)
• Organ dysfunction: Altered mental status from metabolic acidosis and poor cerebral perfusion, dark-colored urine suggesting myoglobinuria or hemolysis, reduced urine output reflecting prerenal azotemia

• Recovery phase (days 7-10 onward): Patients who survive the critical phase typically show dramatic clinical improvement within 24-48 hours as hemodynamic stability returns and plasma reabsorption occurs. Return of appetite, resolution of abdominal pain, and improvement in platelet count and hematocrit mark entry into recovery phase. Convalescence is often prolonged, with patients reporting fatigue, depression, and malaise for weeks to months.

• Physical examination findings: Early in febrile phase, physical examination typically reveals only fever, conjunctival erythema, and perhaps mild pharyngeal erythema without exudate (distinguishing from bacterial pharyngitis). The tourniquet test (inflation of blood pressure cuff to midway between systolic and diastolic pressure for 5 minutes, counting petechiae appearing distal to cuff) has sensitivity 40-60% for identifying dengue hemorrhagic fever but is rarely used clinically given insensitivity. Hepatomegaly (palpable liver edge below costal margin) is present in approximately 40% of cases and correlates with elevated transaminases. Pleural effusions may be noted on lung auscultation (diminished breath sounds, dullness to percussion) or more commonly detected on imaging during critical phase.

• Important clinical variants:
• Dengue hemorrhagic fever (DHF): Defined as dengue fever with hemorrhagic manifestations (positive tourniquet test or spontaneous bleeding) and thrombocytopenia (<100,000/μL) with evidence of plasma leakage (hematocrit elevation ≥20%, pleural effusion, or ascites); DHF occurs in approximately 2.5% of dengue infections but in up to 50% of secondary infections with the "wrong" serotype
• Dengue shock syndrome (DSS): Dengue hemorrhagic fever with evidence of circulatory failure; mortality approaches 10-15% even with treatment and may exceed 40% without fluid resuscitation
• Asymptomatic or mild dengue: Approximately 25% of dengue infections are entirely asymptomatic or present with only mild symptoms lacking fever or systemic manifestations
• Dengue in special populations: Pregnant women may transmit dengue vertically to neonates with severe congenital dengue; elderly patients show higher rates of severe dengue and atypical presentations including altered mental status disproportionate to systemic symptoms

• Virologic confirmation (RT-PCR): Reverse transcription polymerase chain reaction (RT-PCR) targeting dengue viral RNA is the gold-standard diagnostic test, with sensitivity approaching 95-100% when performed during viremia (febrile phase and first 3-5 days after defervescence). RT-PCR can identify specific serotype, enabling distinction from other flaviviruses and permitting prognostication regarding hemorrhagic risk in subsequent infections. Serum viral culture during acute viremia is less sensitive than RT-PCR and primarily used for research purposes. Quantitative viremia (viral load determination) correlates with hemorrhagic risk, with higher viremia loads associated with increased dengue hemorrhagic fever incidence.

• Serologic testing (IgM and IgG antibodies): IgM antibodies become detectable 3-5 days after symptom onset and persist for 2-3 months, making IgM-ELISA most useful for confirming acute infection in patients presenting during critical or recovery phases when viremia may have cleared. IgM positivity defines primary infection. IgG antibodies appear after 1 week of illness and persist for years, permitting identification of prior dengue exposure; IgG positivity in the absence of IgM with symptoms suggests secondary dengue infection (though serologic cross-reactivity with other flaviviruses including West Nile virus, Zika virus, and yellow fever virus can complicate interpretation). In endemic areas, IgG seroprevalence >80% is typical in adult populations. Commercially available ELISA assays for IgM and IgG carry variable sensitivity and specificity; rapid bedside tests show lower accuracy than laboratory-based ELISA.

• Complete blood count and coagulation studies:
• Platelets: Serial platelet counts represent a critical prognostic marker; thrombocytopenia (<100,000/μL) supports dengue diagnosis and predicts progression to hemorrhagic disease. Platelet nadir typically occurs around day 3-5 of illness. A rapid drop in platelet count of >50% day-to-day, particularly in the context of rising hematocrit, portends severe dengue with shock risk. Patients with platelets <50,000/μL carry particular bleeding risk.
• Hematocrit/hemoglobin: Serial hematocrit measurements are more informative than a single value; hematocrit elevation of ≥20% above baseline (or ≥40% in children with no baseline) indicates plasma leakage and is a criterion for dengue hemorrhagic fever diagnosis. Hematocrit values >50% are common in dengue shock syndrome. Paradoxically, hemoglobin may be normal or elevated despite bleeding due to hemoconcentration from plasma loss; significant anemia suggests ongoing hemorrhage.
• White blood cell count: Dengue typically causes leukopenia (WBC <4,000/μL) early in febrile phase, with relative lymphocytosis, followed by recovery toward normal values during critical phase. WBC >10,000/μL should prompt consideration of bacterial superinfection or alternative diagnosis.
• Coagulation panel: Prolonged PT (INR often 1.5-2.0 in uncomplicated dengue, >3.0 in severe dengue) exceeding prolonged aPTT reflects

Immediate triage (WHO groups A/B/C)

• Group A (no warning signs, tolerating oral intake): outpatient management with oral rehydration and strict return precautions; daily CBC and hematocrit during defervescence, since the critical phase begins as fever breaks.
• Group B (warning signs, or comorbidity/pregnancy/infancy/elderly): admit for isotonic crystalloid and serial hematocrit/platelet monitoring.
• Group C (severe dengue: shock, severe bleeding, or organ failure): emergency resuscitation.

First-line therapy

• Isotonic crystalloid (lactated Ringer's or normal saline): the cornerstone of severe dengue care. Plasma leakage is transient, so fluids are titrated to perfusion markers — urine output, pulse pressure, and falling hematocrit — then tapered rapidly once leakage stops.
• Antipyretic/analgesic — acetaminophen: the only recommended agent, with attention to cumulative dose given concurrent hepatitis.

Escalation

• Repeat crystalloid boluses, then colloid (albumin or starch alternatives per local practice) for shock refractory to crystalloid with persistently rising hematocrit.
• Packed red blood cells / whole blood for clinically significant bleeding or for shock with a falling hematocrit — the signature of concealed hemorrhage rather than leakage.
• Vasopressors (norepinephrine) only after volume repletion, since dengue shock is primarily hypovolemic.
• No definitive or surgical management exists; invasive procedures and IM injections are deferred while thrombocytopenic.

Contraindicated / not recommended

• NSAIDs and aspirin: platelet inhibition, gastric erosion, and AKI risk; aspirin additionally risks Reye syndrome in children.
• Prophylactic platelet transfusion for isolated thrombocytopenia without bleeding — not recommended by WHO/CDC.
• Corticosteroids and IVIG: no proven benefit.
• Over-resuscitation into the reabsorption phase, which precipitates pulmonary edema.

Emergencies of the disease

• Dengue shock syndrome: profound plasma leakage narrows pulse pressure before systolic pressure falls; the signal is a narrowed pulse pressure with rising hematocrit and cool, clammy extremities despite an alert patient. Untreated it progresses to irreversible shock, lactic acidosis, and multiorgan failure.
• Severe hemorrhage: thrombocytopenia plus platelet dysfunction, endothelial injury, and consumptive coagulopathy produce GI bleeding, menorrhagia, or intracranial hemorrhage. Signaled by hematemesis/melena with a falling hematocrit — falling hematocrit in a leaking patient means bleeding, not improvement.
• Acute liver failure: immune-mediated and direct hepatocyte injury; heralded by transaminases in the thousands, rising INR, hypoglycemia, and encephalopathy.
• Dengue myocarditis: cytokine-mediated myocyte dysfunction causing shock that fails to respond to volume; troponin elevation, arrhythmias, and reduced ejection fraction on echocardiography.

Other organ complications

• Acute kidney injury: prerenal from hypovolemia, plus acute tubular necrosis and rhabdomyolysis; oliguria with a rising creatinine.
• Neurologic ("expanded dengue syndrome"): encephalopathy from hepatic failure/hyponatremia, true encephalitis, and post-infectious Guillain-Barré or ADEM.
• Hemophagocytic lymphohistiocytosis: persistent fever after the expected critical phase with cytopenias, markedly elevated ferritin, and hypertriglyceridemia.
• Obstetric: vertical transmission near delivery, prematurity, and postpartum hemorrhage.

Complications of treatment

• Fluid overload / pulmonary edema: the commonest iatrogenic harm, occurring when crystalloid is continued into the reabsorption phase; new respiratory distress, orthopnea, and worsening pleural effusions as hematocrit falls. This is an emergency requiring fluid cessation and a loop diuretic.
• NSAID or aspirin exposure: amplified GI bleeding, AKI, and Reye syndrome in children.
• Transfusion-associated circulatory overload and alloimmunization from unnecessary platelet transfusion.
• Bleeding from procedures: IM injections, arterial punctures, and nasogastric tubes during thrombocytopenia.

• Defervescence is the danger point: a returned traveler who "feels better" as the fever breaks on day 3–7 is entering the critical phase of plasma leakage. The stem that says "fever resolved but the patient became lethargic with abdominal pain and vomiting" is describing warning signs, not recovery.
• Best next step in any febrile returned traveler is to exclude malaria with thick and thin blood smears before settling on dengue. This is the most commonly missed "next step" on Step 2 CK; falciparum malaria also causes fever with thrombocytopenia.
• The triad examiners love: leukopenia + thrombocytopenia + elevated transaminases in a febrile traveler from the tropics. Leukopenia argues against bacterial sepsis; leukocytosis should make you rethink the diagnosis.
• NS1 antigen plus RT-PCR early, IgM later: within the first week NS1/PCR are the tests; after roughly a week IgM ELISA takes over. Do not order convalescent serology on a day-2 patient.
• Secondary infection with a different serotype drives severe dengue through antibody-dependent enhancement — the single association most often tested, and the reason dengue vaccination is restricted to the previously infected.
• Acetaminophen only. Aspirin and NSAIDs are contraindicated; aspirin in a child additionally raises Reye syndrome. A stem offering ibuprofen for myalgia is the trap.
• Do not transfuse platelets for a low count alone — treat bleeding and hypovolemia, not the number. Isotonic crystalloid, titrated to a falling hematocrit and adequate urine output, is the therapeutic answer.
• Distinguish the arboviral look-alikes: chikungunya causes prostrating, often persistent polyarthritis; Zika causes prominent pruritic rash and nonpurulent conjunctivitis with congenital microcephaly; dengue is the one with breakbone myalgia, hemoconcentration, and hemorrhage.